Type II 4-phosphatase CRISPR Activation Plasmid (h): sc-402205-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Type II 4-phosphatase CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Type II 4-phosphatase CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Type II 4-phosphatase CRISPR Activation Plasmid (h) and Type II 4-phosphatase CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the INPP4B transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Type II 4-phosphatase Antibody (3F2): sc-293234
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Type II 4-phosphatase CRISPR Activation Plasmid (h) | sc-402205-ACT | 20 µg | $397.00 |
INPP4B encodes type II inositol polyphosphate 4-phosphatase B, a lipid phosphatase that hydrolyzes phosphatidylinositol 3,4-bisphosphate to phosphatidylinositol 3-phosphate, thereby shaping phosphoinositide composition at cellular membranes. Through this activity, INPP4B influences PI3K/AKT signal transduction, endosomal trafficking, and cytoskeleton-associated processes that control proliferation, survival, and migration. Altered INPP4B expression or pathway context has been associated with dysregulated phosphoinositide signaling in multiple disease-relevant settings, including cancer biology and metabolic signaling. As a regulator of membrane-proximal signaling nodes, INPP4B is frequently examined for its effects on pathway amplitude, feedback control, and cell-state transitions.
Type II 4-phosphatase CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous INPP4B expression without altering the underlying DNA sequence.
Type II 4-phosphatase CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the INPP4B locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the INPP4B transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Type II 4-phosphatase expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native INPP4B locus and enabling the study of Type II 4-phosphatase-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Type II 4-phosphatase pathway restoration in tumor cells with silenced or reduced INPP4B expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.